Ornithine Decarboxylase mRNA Expression in Curatively Resected Non-Small-Cell Lung Cancer

被引:9
|
作者
Grimminger, Peter P. [1 ]
Schneider, Paul M. [2 ]
Metzger, Ralf
Vallboehmer, Daniel
Danenberg, Kathleen D. [3 ]
Danenberg, Peter V. [4 ]
Hoelscher, Arnulf H.
Brabender, Jan
机构
[1] Univ Cologne, Dept Gen Visceral & Canc Surg, Univ Clin Cologne, D-50937 Cologne, Germany
[2] Univ Clin Zurich, Dept Visceral & Transplant Surg, Zurich, Switzerland
[3] Response Genet Inc, Los Angeles, CA USA
[4] Univ So Calif, Fac Biochem & Mol Biol, Los Angeles, CA USA
关键词
beta-actin; Biomarkers; DFMO; Nontumorous lung tissue; Real-time RT-PCR; DL-ALPHA-DIFLUOROMETHYLORNITHINE; CHI-SQUARE STATISTICS; POLYAMINE METABOLISM; PANCREATIC-CANCER; ESOPHAGEAL CANCER; BREAST-CANCER; GROWTH; ADENOCARCINOMA; TRANSFORMATION; CARCINOMA;
D O I
10.3816/CLC.2010.n.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The effect of ornithine decarboxylase (ODC) on the pathogenesis of non-small-cell lung cancer (NSCLC) remains poorly investigated. Hence, the aim of this study was to explore the potential role of ODC mRNA expression as a prognostic biomarker in patients with curatively resected NSCLC. Patients and Methods: A total of 91 tumor and matching nontumorous lung tissue samples from patients with NSCLC were analyzed using a quantitative realtime reverse-transcriptase polymerase chain reaction method. The relative ODC mRNA expression was measured in tumorous and nontumorous lung tissue using beta-actin as a reference gene. Squamous cell carcinoma was found in 43 patients (47%), adenocarcinoma in 33 (36%), and large-cell carcinoma in 15 of the patients (17%). All patients' disease was R0 resected. Results: Ornithine decarboxylase was detected in all 91 tumor and nontumorous lung tissue samples. The median tumorous expression of 9.11 (range, 0.92-155.35) was significantly elevated compared with the median ODC expression of 7.89 (range, 0.0-45.8) in nontumorous lung tissue. Ornithine decarboxylase expression levels were not associated with any clinicopathologic parameters. Using an ODC/beta-actin ratio of 10 as a cutoff, tumorous ODC (tODC) expression is a significant prognostic factor in NSCLC. The ODC ratio between tumorous and nontumorous expression was even more prognostic. Moreover, Cox proportional hazards model analysis showed ODC expression to be an independent prognostic factor. Conclusion: In this study, ODC is shown to have a prognostic potential in NSCLC. Low levels of tODC expression are associated with a more aggressive tumor biology. Also, an increase of ODC mRNA expression during carcinogenesis seems to have a favorable prognostic effect. Measuring the ODC expression in patients with NSCLC could aid in further chemotherapy decisions. Our results suggest that further investigation of ODC mRNA expression in NSCLC may be warranted.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 50 条
  • [41] Single Thymic Gland Metastasis From Resected Non-Small-Cell Lung Cancer
    Rena, Ottavio
    Sacchetti, Gian Mauro
    Ramponi, Antonio
    Roncon, Alberto
    Baietto, Guido
    Casadio, Caterina
    ARCHIVOS DE BRONCONEUMOLOGIA, 2012, 48 (11): : 423 - 424
  • [42] Outcome and prognostic factors of resected non-small-cell lung cancer invading the diaphragm
    Galetta, Domenico
    Borri, Alessandro
    Casiraghi, Monica
    Gasparri, Roberto
    Petrella, Francesco
    Tessitore, Adele
    Serra, Maria
    Guarize, Juliana
    Spaggiari, Lorenzo
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2014, 19 (04) : 632 - 636
  • [43] Non-small-cell lung cancer
    Cesare Gridelli
    Antonio Rossi
    David P. Carbone
    Juliana Guarize
    Niki Karachaliou
    Tony Mok
    Francesco Petrella
    Lorenzo Spaggiari
    Rafael Rosell
    Nature Reviews Disease Primers, 1
  • [44] Adjuvant chemotherapy for resected non-small-cell lung cancer - ANITA takes the stage
    Azzoli, Christopher G.
    LANCET ONCOLOGY, 2006, 7 (09): : 701 - 703
  • [45] Global histone modifications predict prognosis of resected non-small-cell lung cancer
    Barlesi, Fabrice
    Giaccone, Giuseppe
    Gallegos-Ruiz, Marielle I.
    Loundou, Anderson
    Span, Simone W.
    Lefesvre, Pierre
    Kruyt, Frank A. E.
    Rodriguez, Jose Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) : 4358 - 4364
  • [46] Adjuvant chemotherapy for completely resected non-small-cell lung cancer. Reply
    Keller, SM
    Johnson, DH
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (09): : 690 - 690
  • [47] Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters
    Peters, Solange
    Weder, Walter
    Dafni, Urania
    Kerr, Keith M.
    Bubendorf, Lukas
    Meldgaard, Peter
    O'Byrne, Kenneth J.
    Wrona, Anna
    Vansteenkiste, Johan
    Felip, Enriqueta
    Marchetti, Antonio
    Savic, Spasenija
    Lu, Shun
    Smit, Egbert
    Dingemans, Anne-Marie
    Blackhall, Fiona H.
    Baas, Paul
    Camps, Carlos
    Rosell, Rafael
    Stahel, Rolf A.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) : 1675 - 1684
  • [48] Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer with Lymphovascular Invasion Response
    Rami-Porta, Ramon
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) : E9 - E10
  • [49] SITES OF FIRST DISTANT RECURRENCE IN RESECTED NON-SMALL-CELL LUNG-CANCER
    URSCHEL, JD
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 110 (01): : 286 - 286
  • [50] Non-small-cell lung cancer
    Gridelli, Cesare
    Rossi, Antonio
    Carbone, David P.
    Guarize, Juliana
    Karachaliou, Niki
    Mok, Tony
    Petrella, Francesco
    Spaggiari, Lorenzo
    Rosell, Rafael
    NATURE REVIEWS DISEASE PRIMERS, 2015, 1